The Bridge to Scale project is an implementation science initiative that seeks to move oral Pre Exposure Prophylaxis (PrEP) from research and demonstration settings into a large-scale public health response in Kenya. Over 20,000 people at highest risk of HIV infection will receive oral PrEP, which will be integrated within existing HIV combination prevention services. This project will demonstrate the incredible potential of PrEP and generate evidence that population-level PrEP interventions are feasible and effective in low- and middle-income countries, which bear the brunt of the world’s HIV burden.

The project will function as a learning laboratory to identify and document the barriers and enablers to PrEP uptake. Ultimately, the project will develop an affordable, effective, sustainable and replicable model for oral PrEP scale-up.
1. Demonstrate that oral Pre Exposure Prophylaxis works to reduce HIV incidence among sub-populations at highest risk of HIV infection when implemented at a population level in “real life” routine service delivery

2. Develop and document an acceptable, affordable, and replicable approach to launch and scale-up the use of oral Pre Exposure Prophylaxis among those at highest risk of HIV

3. Ensure political, donor, and community support for the scale-up of oral Pre Exposure Prophylaxis
For more information:
Daniel Were, Project Director
Daniel.Were@jhpiego.org
Tel: (+254) 732 134 000
TARGET AND GEOGRAPHIC LOCATION

**COAST cluster**
- Mombasa, Kwale, Kilifi, Taita Taveta
- B2S Oral PrEP
- Target: 5,783

**NAIROBI cluster**
- Nairobi, Machakos, Kiambu
- B2S Oral PrEP
- Target: 10,712

**LAKE cluster**
- Kisumu, Homa Bay and Kisii
- B2S Oral PrEP
- Target: 4,281
What Is PrEP For HIV Prevention?

Oral Pre Exposure Prophylaxis is a new way for people who are HIV-negative but at high risk of infection to protect themselves. It requires taking a pill daily containing tenofovir and emtricitabine (TDF/FTC). Modelling from recent clinical trials found oral PrEP is highly effective (94–99%) at preventing HIV infection if taken according to the prescribed regimen. The World Health Organization now recommends oral PrEP among populations with a HIV incidence of 3% per year or higher. (WHO, 2015). Kenya has included Pre Exposure Prophylaxis in the revised national guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.
Partners

With funding from the Bill and Melinda Gates Foundation, Jhpiego leads the consortium of National AIDS and STIs Control Program (NASCOP), Population Services-Kenya (PS Kenya), Avenir Health, and International Center for Reproductive Health Kenya (ICRHK).